Nuvei Consensus Price Target Climbs $21 After Q2 Results Impress

On August 10, Nuvei Corporation (TSX: NVEI) reported its second quarter financial results. The company reported revenues of $178 million, which grew over 100% since last year. The company reported a gross profit of $145.1 million, also growing over 100%. The company had a gross margin of 81.4% The firm also posted a net income of $38 million and earnings per share of $0.26.

More than half of the 12 analysts covering the name raised their 12-month price targets on Nuvei, bringing the analyst consensus to $109.69, up from the prior $88.29 consensus price target. Out of the 12 analysts, 3 have strong buy ratings, 7 have buy ratings, and 2 analysts have hold ratings. The street high sits at $134.40 from Cowen and Company while the lowest target comes in at $84.

BMO Capital Markets was one of the firms to increase their price target. They increased their target to $109 from $72 and reiterated their market perform rating, saying that the company is growing revenue faster than expected.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

BMO had a $0.36 earnings per share estimate and the consensus was $0.34, while revenue grew over 100% which was primarily driven by higher volumes and better take rates. They also say that the Nuvei updated guidance is extremely bullish, with them expecting $88-91 billion in volume, and $690-705 million in revenue.

Below you can see BMO’s updated third quarter, 2021, and 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

8 Mining Stocks Our Viewers Asked Us to Review | Sept 14th-18th

Canada Is Finally Fast-Tracking New Mines | John Passalacqua – First Phosphate

Gold & Silver Just Added $2 Billion to This Project | Aya Gold – Bourmadine PEA

Recommended

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Japan Gold Lands $50 Million in Committed Capital Through Solidcore Alliance

Related News

BMO: Tronox Holdings $27 Buyout Offer Is Underwhelming

On September 13, Reuters News reported that Apollo Global Management approached Tronox Holdings (NYSE: TROX)...

Wednesday, September 15, 2021, 03:13:00 PM

Well Health: Canaccord Reiterates Ratings Following Recent Acquisition

Last week WELL Health Technologies (TSX: WELL) announced their latest acquisition, a majority stake in...

Friday, September 10, 2021, 03:29:00 PM

Aurora Cannabis: Consensus Estimates Point To Flat Quarterly Growth

Aurora Cannabis (TSX: ACB) (NYSE: ACB) announced that they will be reporting their fiscal third quarter...

Thursday, May 13, 2021, 12:31:00 PM

BMO Gives Cameco Price Target A Lift To $33

On February 9th, Cameco (TSX: CCO) reported its full-year 2021 financial results. The company reported...

Monday, February 14, 2022, 02:59:00 PM

Canaccord Raises CloudMD Price Target To $1.75 Following Financial Results

On Monday, CloudMD Software & Services (TSXV: DOC) reported its second-quarter financials. CloudMD’s revenue was...

Thursday, September 3, 2020, 02:37:00 PM